Back to search results

A Study of LY3439539 for Alzheimer's Disease

This study is testing a drug called LY3439539, which is given through an IV (intravenous infusion). Researchers want to see how this drug affects specific proteins in the spinal fluid of people with Alzheimer's disease. LY3439539 is a monoclonal antibody, a type of protein that can target specific substances in the body. To join, you should be between 50 and 85 years old, have a diagnosis of Alzheimer's disease with memory changes for at least 6 months, and meet certain scores on a memory test (Mini Mental Score Examination of 16-24). You also need to meet specific plasma pTau criteria (a biomarker for Alzheimer's) and have a body mass index between 17 and 32. The main goal is to measure changes in a protein called Neurofilament Light Chain (NfL) in your spinal fluid over 24 weeks. The study plans to enroll 30 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants.
What's involved
Participation in the study will last approximately 9 months, with visits about once a month.
Compensation
Not stated in the trial record.
Follow-up
Changes in spinal fluid Neurofilament Light Chain (NfL) will be measured through the end of the Follow-up Period (Week 24).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07598370

A Study of LY3439539 in Participants With Alzheimer's Disease

Recruiting
PHASE1Ages 50–85InterventionalBasic science
Eli Lilly and Company
~30 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:LY3439539

At a glance

Recruiting sites
5 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL)
Measured over Baseline through end of the Follow-up Period (Week 24)

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's DiseaseMicrotubule-Associated Protein Tau

NCT07598370

Where you'd take part

This study runs at 11 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Austin Health - Heidelberg Repatriation Hospital

    Ivanhoe, Australiastudy coordinator listed

    Recruiting

  • Charter Research

    Orlando, Floridastudy coordinator listed

    Not yet recruiting

  • Christchurch Neurology Trials

    Christchurch, New Zealandstudy coordinator listed

    Not yet recruiting

  • Flinders Medical Centre

    Adelaide, Australiastudy coordinator listed

    Not yet recruiting

  • Healthy Brain Clinic

    Long Beach, Californiastudy coordinator listed

    Not yet recruiting

  • Irvine Clinical Research

    Irvine, Californiastudy coordinator listed

    Not yet recruiting

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singaporestudy coordinator listed

    Recruiting

  • Macquarie University Hospital

    Macquarie University, Australiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have gradual and progressive change in memory function reported by the participant or informant for 6 months or longer consistent with a diagnosis of dementia due to Alzheimer's disease
Have a Mini Mental Score Examination score of 16 to 24, inclusive
Meet plasma pTau criteria, as defined by the sponsor
Have body mass index within the range of 17 and 32 kilograms per square meter (kg/m²) (inclusive) at screening
Are women not of childbearing potential and men willing to practice effective contraception throughout the study.
Have adequate premorbid literacy, vision, and hearing throughout the study duration and able to complete study procedures.
Have at least 1, and up to 2, study partners who are in frequent contact with the participant (defined as at least 10 hours per week).

Exclusion

Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
Have a screening MRI that shows evidence of significant abnormality.
Have history of suicidal behavior, or a lifetime history of suicide attempt or acute suicidality.
Have a history of
Severe or ongoing allergy or hypersensitivity reactions
Hypersensitivity to immunizations or immunoglobulins
Two or more clinically significant or severe drug allergies,
Intolerance to topical corticosteroids or severe posttreatment hypersensitivity reactions
Have current serious or unstable illnesses, including hepatic, renal, gastroenterological, respiratory, cardiovascular, neurologic (other than AD), psychiatric, endocrinologic, immunologic, hematologic disease, or other conditions
Require treatment with another monoclonal antibody or have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
Have criteria that would preclude a lumbar puncture (LP).
Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
Have a current exposure to amyloid-targeting therapies (ATTs). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.

What this trial measures

  • Change from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL)Baseline through end of the Follow-up Period (Week 24)